Optimizing brain stimulation for epilepsy treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine the most effective stimulation parameters for patients with epilepsy using Deep Brain Stimulation (DBS) targeting the Anterior Nucleus of the Thalamus (ANT). It will compare the effectiveness of low frequency versus high frequency stimulation to identify which approach yields better outcomes for seizure control. Patients who have already received a brain stimulation device will be monitored over a period of 6-8 months to assess the impact of these different stimulation settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who are implanted with a brain stimulation device targeting the anterior nucleus of the thalamus per Mayo Clinic standard of care

Exclusion Criteria:

* Patients for whom clinical follow-up is not expected during the initial 6-8 months following implant

Where it's running

• Mayo Clinic Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Amy Headlee
• Email: headlee.amy@mayo.edu
• Phone: 507-538-4107

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-personalized Medilepsy app to help teens and young adults with epilepsy manage medicines and transition to adult care

  This trial tests whether an AI-personalized Medilepsy app helps underserved adolescents and young adults with epilepsy (ages 14–24) take their anti-seizure medicines and prepare for adult care better than the standard app.

  Recruiting at 2 sites University of Central Florida · Orlando, Florida and 1 other locations · NCT07445074

• Project PENGUIN: Profiling phenotypic, epigenetic, and neurogenetic traits in rare neurodevelopmental disorders

  This project will try to collect clinical data, genetic and epigenetic samples, imaging, and skin-derived cell models from people with rare neurogenetic disorders like SYT1/BAGOS to help track disease and support future treatments.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07329257

• Long-term RAP-219 treatment for adults with focal onset seizures

  This trial will try RAP-219, an investigational anti-seizure medication, in adults with refractory focal seizures to see if it is safe long-term and helps reduce seizures.

  Recruiting at 7 sites Phase 2 Rapport Therapeutics Inc. · Boise, Idaho and 6 other locations · NCT07219407

• Vascular risk screening and management after late-onset seizures

  This project will test whether screening and treating blood pressure, cholesterol, BMI and other vascular risks in people who have their first unprovoked seizure after age 50 can lower their future risk of stroke and heart disease.

  Recruiting at 3 sites Sahlgrenska University Hospital · Borås and 2 other locations · NCT07116330

• Detecting thalamus seizures using a Percept deep brain stimulator

  This project will test whether the Medtronic Percept DBS device can reliably detect seizures from the thalamus in adults with drug-resistant epilepsy.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06700356

• Low-intensity focused ultrasound treatment for drug-resistant epilepsy

  This study is testing if low-intensity focused ultrasound can help people with drug-resistant temporal lobe epilepsy have fewer seizures while they continue taking their regular medications.

  Recruiting at 3 sites Phase 1/2 NaviFUS Corporation · Palo Alto, California and 2 other locations · NCT06388707

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.